ANI Pharmaceuticals (NASDAQ: ANIP) insider plans Form 144 sale of restricted shares

Rhea-AI Filing Summary

ANI Pharmaceuticals insider Stephen P. Carey filed a Form 144 for a proposed sale of common stock. The filing covers 6,163 shares of common stock held through Morgan Stanley Smith Barney LLC, with an aggregate market value of $499,449.52 and 22,734,618 shares of common stock outstanding as of this notice.

The securities to be sold relate to Restricted Stock Awards granted on April 6, 2019. The planned sale date is July 29, 2026 on NASDAQ. Over the prior three months, sales under a Rule 10b5-1 trading plan totaled 3,313 shares for $284,918.00 on July 2, 2026, 2,850 shares for $239,742.57 on June 29, 2026, and 3,312 shares for $264,960.00 on June 5, 2026.

Key Figures

Shares proposed for sale: 6,163 shares Aggregate market value of proposed sale: $499,449.52 Shares outstanding: 22,734,618 shares +4 more

7 metrics

Shares proposed for sale 6,163 shares Common stock covered by Form 144 notice

Aggregate market value of proposed sale $499,449.52 Value of 6,163 shares of common stock

Shares outstanding 22,734,618 shares Common stock outstanding referenced in the notice

Planned sale date 07/29/2026 Intended date for selling 6,163 shares on NASDAQ

10b5-1 sale on 07/02/2026 3,313 shares for $284,918.00 Common stock sold under Rule 10b5-1 plan

10b5-1 sale on 06/29/2026 2,850 shares for $239,742.57 Common stock sold under Rule 10b5-1 plan

10b5-1 sale on 06/05/2026 3,312 shares for $264,960.00 Common stock sold under Rule 10b5-1 plan

Key Terms

Form 144, Restricted Stock Awards, Rule 10b5-1

3 terms

Form 144 regulatory

"Stephen P. Carey filed a Form 144 for a proposed sale"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Awards financial

"securities to be sold relate to Restricted Stock Awards granted"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

Rule 10b5-1 regulatory

"Over the prior three months, sales under a Rule 10b5-1 trading plan"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 04:22 PM Accepted by SEC EDGAR 07/29/2026 - 04:21 PM Learn about SEC filing dates

FAQ

What does the ANIP Form 144 filed by Stephen P. Carey disclose?

The Form 144 discloses a proposed sale of 6,163 shares of ANI Pharmaceuticals common stock by insider Stephen P. Carey, related to Restricted Stock Awards and planned for trading on NASDAQ.

How many ANIP shares are proposed to be sold and what is their value?

The proposed sale covers 6,163 common shares of ANI Pharmaceuticals with an aggregate market value of $499,449.52, based on the values stated in the Form 144 notice.

What is the planned sale date for Stephen P. Carey’s ANIP shares?

The planned sale date for the 6,163 ANIP common shares covered by the Form 144 is July 29, 2026, with trading expected to occur on the NASDAQ market according to the filing.

How many ANIP shares are outstanding according to this Form 144?

According to the Form 144, there are 22,734,618 shares of ANI Pharmaceuticals common stock outstanding, which serves as a reference figure separate from the shares proposed for sale.

What recent ANIP stock sales under Rule 10b5-1 are reported in this Form 144?

The Form 144 lists prior Rule 10b5-1 sales: 3,313 shares for $284,918.00 on July 2, 2026, 2,850 shares for $239,742.57 on June 29, 2026, and 3,312 shares for $264,960.00 on June 5, 2026.

What type of ANIP awards are associated with the shares in this Form 144?

The shares proposed for sale are associated with Restricted Stock Awards dated April 6, 2019, with the issuer identified as ANI Pharmaceuticals in the Form 144 disclosure.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6163	499449.52	22734618	07/29/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/06/2019	Restricted Stock Awards	Issuer			6163	04/06/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for STEPHEN P CAREY TODSUBJECT TO STA RULES 104 Carnegie Center Drive, Suite 300 Princeton NJ 08540	Common	07/02/2026	3313	284918.00
10b5-1 Sales for STEPHEN P CAREY TODSUBJECT TO STA RULES 104 Carnegie Center Drive, Suite 300 Princeton NJ 08540	Common	06/29/2026	2850	239742.57
10b5-1 Sales for STEPHEN P CAREY TODSUBJECT TO STA RULES 104 Carnegie Center Drive, Suite 300 Princeton NJ 08540	Common	06/05/2026	3312	264960.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)